On the other hand, PPT ginsenosides have pharmacological effects on the central nervous and cardiovascular systems [30], and PPT reportedly acts as a PPARγ antagonist [31]; thus, targeting PPARγ is considered a promising treatment option for obesity. Here, PPARG is linked to obesity due to melanocortin 4 receptor deficiency.